Ionis Pharmaceuticals (NASDAQ:IONS) EVP Eric Swayze Sells 15,642 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 15,642 shares of the business’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $81.76, for a total value of $1,278,889.92. Following the transaction, the executive vice president directly owned 32,105 shares of the company’s stock, valued at $2,624,904.80. This represents a 32.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Eric Swayze also recently made the following trade(s):

• On Friday, January 30th, Eric Swayze sold 6,179 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $82.93, for a total value of $512,424.47.
• On Friday, January 16th, Eric Swayze sold 49 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $75.97, for a total value of $3,722.53.
• On Friday, January 16th, Eric Swayze sold 9,884 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $75.34, for a total transaction of $744,660.56.
• On Friday, January 2nd, Eric Swayze sold 23,463 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $79.12, for a total transaction of $1,856,392.56.

Ionis Pharmaceuticals Price Performance

Shares of Ionis Pharmaceuticals stock opened at $80.60 on Friday. The company has a debt-to-equity ratio of 0.96, a current ratio of 2.79 and a quick ratio of 2.78. The company has a market cap of $13.06 billion, a PE ratio of -47.69 and a beta of 0.29. The firm has a fifty day moving average price of $80.70 and a two-hundred day moving average price of $69.12. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $23.95 and a fifty-two week high of $86.74.

Wall Street Analyst Weigh In

A number of analysts have commented on IONS shares. HC Wainwright raised their price objective on Ionis Pharmaceuticals from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Needham & Company LLC upped their target price on Ionis Pharmaceuticals from $78.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Raymond James Financial reiterated a “strong-buy” rating and set a $89.00 price target (up previously from $85.00) on shares of Ionis Pharmaceuticals in a research note on Thursday, October 30th. Wall Street Zen cut shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Finally, Piper Sandler raised their price objective on shares of Ionis Pharmaceuticals from $77.00 to $87.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $86.95.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter worth about $25,000. Golden State Wealth Management LLC grew its stake in Ionis Pharmaceuticals by 198.4% during the third quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after buying an additional 250 shares during the last quarter. Mather Group LLC. acquired a new stake in shares of Ionis Pharmaceuticals during the third quarter worth approximately $27,000. Brown Brothers Harriman & Co. bought a new position in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $27,000. Finally, Allworth Financial LP boosted its holdings in shares of Ionis Pharmaceuticals by 231.8% in the 2nd quarter. Allworth Financial LP now owns 740 shares of the company’s stock worth $29,000 after acquiring an additional 517 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.